Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Metsera expects its cash will last into 2027. Two other life science companies went public this past week. Here’s a look at those IPOs: Maze Therapeutics Finds Way to $140M IPO for Chronic ...

Aardvark’s IPO comes amid an uptick in biotech ... far in 2025 include obesity drug developer Metsera, Sionna Therapeutics, kidney disease startup Maze Therapeutics, and Ascentage Pharma.

Its prospectus says that the IPO will fund phase 1 and phase ... in the footsteps of obesity drug developer Metsera and genetic medicines developer Maze Therapeutics, which filed to list on ...

January 31, 2025 Metsera hits $2.7 bln valuation as shares ... January 31, 2025 Biotech firm Maze Therapeutics raises $140 million in US IPO Maze Therapeutics said on Thursday that it raised ...

Aardvark’s IPO comes amid an uptick in biotech public offerings since the start of the year. Other companies that have gone public so far in 2025 include obesity drug developer Metsera, Sionna ...

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

Guggenheim has initiated coverage of Metsera (MTSR) with a buy rating, citing the company's obesity drug candidates. Read ...

Maze Therapeutics receives positive ratings following recent IPO Intuit earnings beat by $0.74, revenue topped estimates Workday earnings beat by $0.14, revenue topped estimates ...

The newly listed clinical-stage biotechnology company, Metsera Inc. rose 15.01% on Monday as the broader markets declined.